Doxorubicin levels in the serum and ascites of patients with ovarian cancer

European Journal of Surgical Oncology

Volumn 33, Issue 2, 2007, Pages 213-215

  Gotlieb, W H ^a   Bruchim, I ^a   Ben Baruch, G ^b   Davidson, B ^c   Zeltser, A ^b   Andersen, A ^d   Olsen, H ^d  

^a MCGILL UNIVERSITY   (Canada)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF OSLO   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Ascites; Chemotherapy; Doxorubicin; Ovarian cancer; Paracentesis; Toxicity

Indexed keywords

7 DEOXYADRIAMYCINONE; 7 DEOXYDOXORUBICINOLONE; DOXORUBICIN; DOXORUBICINOL; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASCITES FLUID; ASCITES TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; OVARY CANCER; OVARY CARCINOMA; PARACENTESIS; PERITONEAL CAVITY; PRIORITY JOURNAL; RECURRENT CANCER; SINGLE DRUG DOSE; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ASCITES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NAPHTHACENES; OVARIAN NEOPLASMS; PARACENTESIS; PROGNOSIS;

EID: 33847664734     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.11.006     Document Type: Article

References (12)

1. Armstrong D.K., Bundy B., Wenzel L., et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 1 (2006) 34-43
2. Vermorken J.B. The role of anthracyclines in second-line therapy of ovarian cancer. Int J Gynecol Cancer 13 Suppl. 2 (2003) 178-184
3. Speth P.A., van Hoesel Q.G., and Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15 (1988) 15-31
4. Gotlieb W.H., Feldman B., Feldman-Moran O., et al. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer. Gynecol Oncol 71 (1998) 381-385
5. Andersen A., Warren D.J., and Slordal L. A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma. Ther Drug Monit 15 (1993) 455-461
6. Jacquet P., and Sugarbaker P.H. Peritoneal-plasma barrier. Cancer Treat Res 82 (1996) 53-63
7. Kimura M., Konno T., Miyamoto Y., Kojima Y., and Maeda H. Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses. Anticancer Res 18 (1998) 2547-2550
8. Lazo J.S., and Schwartz P.E. Rapid distribution of adriamycin in the ascitic and pleural fluid of women with ovarian carcinomas. Gynecol Oncol 21 (1985) 65-72
9. Gelderblom H., Loos W.J., Verweij J., de Jonge M.J., and Sparreboom A. Topotecan lacks third space sequestration. Clin Cancer Res 6 (2000) 1288-1292
10. Andersen A., Holte H., and Slordal L. Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients. Cancer Chemother Pharmacol 44 (1999) 422-426
11. Gille L., and Nohl H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic Biol Med 23 (1997) 775-782
12. Licata S., Saponiero A., Mordente A., and Minotti G. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Chem Res Toxicol 13 (2000) 414-420